

Performance in Initiating Clinical Trials Q1 2022-2023
First participant recruited

Ethics Committee Number	IRAS Number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site confirmed by Sponsor	Date Site confirmed	Date Site Ready to Start	Date of First Patient Recruited	Source of Delay	Comments
21/LO/0621	301803	A Short-term Exploratory Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Seltorexant as Adjunctive Therapy to Antidepressants in Adolescents with Major Depressive Disorder Who Have an Inadequate Response to an SSRI and Psychotherapy	26/08/2021	26/08/2021	15/11/2021	13/12/2021	06/01/2022	06/01/2022	N/A	Sponsor	Strict eligibility criteria. The current healthcare path for adolescents affected by Major Depressive Disorder includes one of the drugs indicated in the exclusion criteria for the study, so this reduces considerably the possibility of finding suitable participants. The local PI has requested a change in the eligibility criteria to the sponsor.
21/WA/0151	287976	A Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) for the treatment of agitation in patients with dementia of the Alzheimer s type, 20-AVP-786-306	04/01/2021	24/08/2021	17/08/2021	25/08/2021	24/09/2021	23/11/2021	N/A	NHS Provider	Contract was signed before study was ready to open (24.09.2021) but the study didn't open until 60 days into recruiting first participant period (23.11.2021) due to key contact unavailability. After screening 278 people, the study team has not been able to identify an eligible participant willing to take part in the study. Other recruitment strategies, such as recruiting from care homes and GP surgeries, are being considered at present.
21/WA/0360	286005	Social Connections and Unusual Beliefs and Experiences Study (SCUBES)	25/10/2021	25/10/2021	26/11/2021	01/10/2021	21/04/2022	21/04/2022	N/A	Sponsor	The HR checks took longer than expected to employ a research assistant.
22/WM/0013	300550	Impact of Semaglutide in Amyloid Positivity	19/01/2022	26/01/2022	16/03/2022	13/05/2022	19/05/2022	19/05/2022	N/A	Sponsor	After opening the study on our site the sponsor informed us that they are not ready to start.